Molecular mechanisms and drug therapy of metabolism disorders in psoriasis
Background: Psoriasis is a prevalent skin disease affecting approximately 1%–3% of the population and imposes significant medical, social and economic burdens. Psoriasis involves multiple organs and is often complicated with obesity, diabetes, dyslipidemia, and hypertension. Because of the benefits...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2375580 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850249991295074304 |
|---|---|
| author | Yanyang Liang Ying Wang Aihong Peng Junqin Li Kaiming Zhang |
| author_facet | Yanyang Liang Ying Wang Aihong Peng Junqin Li Kaiming Zhang |
| author_sort | Yanyang Liang |
| collection | DOAJ |
| description | Background: Psoriasis is a prevalent skin disease affecting approximately 1%–3% of the population and imposes significant medical, social and economic burdens. Psoriasis involves multiple organs and is often complicated with obesity, diabetes, dyslipidemia, and hypertension. Because of the benefits of lipid-lowering agents and antidiabetic medications for psoriasis, metabolic abnormalities possibly play a pathogenic role in psoriasis.Objective: This review focuses on the impacts of a variety of metabolic disorders on psoriasis and the underlying mechanisms.Results: In psoriasis, enhanced glycolysis, glutamine metabolism and altered fatty acid composition in the psoriatic lesion and plasma result in the excessive proliferation of keratinocytes and secretion of inflammatory cytokines. Altered metabolism is associated with the activation of MTORC signaling pathway and transcription factors such as HIF and S6K1. Therefore, MTORC1 can be a target for the treatment of psoriasis. Additionally, there are diabetes drugs and lipid-lowering drugs including TZDs, GLP-1 RAs, Metformin, statins and fibrates, which improve both metabolic levels and psoriasis symptoms. |
| format | Article |
| id | doaj-art-48f2bbd92bea478993d2d6bf124217ae |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-48f2bbd92bea478993d2d6bf124217ae2025-08-20T01:58:20ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2375580Molecular mechanisms and drug therapy of metabolism disorders in psoriasisYanyang Liang0Ying Wang1Aihong Peng2Junqin Li3Kaiming Zhang4Shanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, ChinaShanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, ChinaShanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, ChinaShanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, ChinaShanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, ChinaBackground: Psoriasis is a prevalent skin disease affecting approximately 1%–3% of the population and imposes significant medical, social and economic burdens. Psoriasis involves multiple organs and is often complicated with obesity, diabetes, dyslipidemia, and hypertension. Because of the benefits of lipid-lowering agents and antidiabetic medications for psoriasis, metabolic abnormalities possibly play a pathogenic role in psoriasis.Objective: This review focuses on the impacts of a variety of metabolic disorders on psoriasis and the underlying mechanisms.Results: In psoriasis, enhanced glycolysis, glutamine metabolism and altered fatty acid composition in the psoriatic lesion and plasma result in the excessive proliferation of keratinocytes and secretion of inflammatory cytokines. Altered metabolism is associated with the activation of MTORC signaling pathway and transcription factors such as HIF and S6K1. Therefore, MTORC1 can be a target for the treatment of psoriasis. Additionally, there are diabetes drugs and lipid-lowering drugs including TZDs, GLP-1 RAs, Metformin, statins and fibrates, which improve both metabolic levels and psoriasis symptoms.https://www.tandfonline.com/doi/10.1080/09546634.2024.2375580Psoriasismetabolism disordersdrug therapyMTORC1 pathwayglucose metabolismlipid metabolism |
| spellingShingle | Yanyang Liang Ying Wang Aihong Peng Junqin Li Kaiming Zhang Molecular mechanisms and drug therapy of metabolism disorders in psoriasis Journal of Dermatological Treatment Psoriasis metabolism disorders drug therapy MTORC1 pathway glucose metabolism lipid metabolism |
| title | Molecular mechanisms and drug therapy of metabolism disorders in psoriasis |
| title_full | Molecular mechanisms and drug therapy of metabolism disorders in psoriasis |
| title_fullStr | Molecular mechanisms and drug therapy of metabolism disorders in psoriasis |
| title_full_unstemmed | Molecular mechanisms and drug therapy of metabolism disorders in psoriasis |
| title_short | Molecular mechanisms and drug therapy of metabolism disorders in psoriasis |
| title_sort | molecular mechanisms and drug therapy of metabolism disorders in psoriasis |
| topic | Psoriasis metabolism disorders drug therapy MTORC1 pathway glucose metabolism lipid metabolism |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2375580 |
| work_keys_str_mv | AT yanyangliang molecularmechanismsanddrugtherapyofmetabolismdisordersinpsoriasis AT yingwang molecularmechanismsanddrugtherapyofmetabolismdisordersinpsoriasis AT aihongpeng molecularmechanismsanddrugtherapyofmetabolismdisordersinpsoriasis AT junqinli molecularmechanismsanddrugtherapyofmetabolismdisordersinpsoriasis AT kaimingzhang molecularmechanismsanddrugtherapyofmetabolismdisordersinpsoriasis |